Category Archives: Cancer

Home / Cancer
5 Posts

For a startup to be successful they need to attract investors that are excited about and believe in the potential for the company to succeed. That means that investors are everything because they can make or break a startup. That is why the new start-up company that Eric Lefkofksy has co-founded., Tempus is proud that they have reached Unicorn status. Unicorn Status is a term used in startup culture to describe when a company has been valued at over 1 billion, while still being privately held. It is very rare, and only a handful of Chicago based companies have achieved this. Reaching Unicorn Status means that a company has been successful at their objective and that investors believe that this success will continue.

For Eric Lefkofsky’s company Tempus, which was founded in 2015, success means that they have been able to help change the way cancer care is implemented. Specifically, they analyze data about cancer treatment patients and then use this data analysis to help oncologists find a better course of treatment. Lefkofsky is a data specialist who co-founded the company because he became interested in helping ensure that cancer patients had a better quality of life.

From the knowledge learned by crunching the numbers and finding out which treatments work for which patients, Lefkofsky, and the company are able to help doctors find a specific course of treatment for specific types of cancers. In the past, oncologists had been prescribing a more or less “one size fits all” treatment plan for their patients without really knowing which treatments are successful for which patients and their particular cancer. Oncologists are able to study the database that Tempus has created and will hopefully make new discoveries about cancer treatment options, thus making the lives of cancer patients easier.

With their latest round of funding, Tempus was able to secure 80 million dollars from donors who were impressed by the way the company is able to use data to change cancer treatment. Some of the investors that helped Tempus reach Unicorn status include new investors Kinship Trust Co, as well as Revolution Growth and New Enterprise Associates.

To Read More Click Here

Yearly spending on health care in the U.S. has increased over the years due to high costs for health care services. Furthermore, most Americans are receiving expensive and extensive health care services. It is also reported that aging and population growth are among the factors contributing to the increase in expenditures.

The prevalence of diseases in the U.S. is associated with different factors for different diseases. Diabetes is one of the diseases that people spend lots of money to treat Diabetes. A large percentage of this money is spent on purchasing pharmaceuticals for diabetes rather than seeking professional health care services. A study on the health care spending found out that people spend highly on the treatment of neck and low back pain.

Children, unlike adults, require a lot of attention when growing up because they are prone to diseases. Organizations such as the Lefkofsky Foundation understand that children need to grow in a safe environment at all costs. To foster this goal, the Lefkofsky Foundation offers financial and technical support to educational, charitable and scientific organizations across the world that focus on children.

To date, the Lefkofsky Foundation has managed to provide financial support to more than 50 organizations. The organization was established by serial entrepreneur, Eric Lefkofsky and his spouse (Elizabeth). Eric and Elizabeth shared a vision to support the community through this organization. Besides being involved with the Lefkofsky Foundation, Eric is also a member of World Business Chicago and Children’s Memorial Hospital in Chicago, which have community interests at heart.

About Eric Lefkofsky

Eric Lefkofsky had an impressive track record when he was pursuing a career in entrepreneurship. Before he became successful, Eric went to law school and sold carpets. His first business venture was known as Brandon Apparel. Later on, he co-created companies such as Echo Global Logistics, a freight logistics firm, and a media-buying tech firm known as MediaBank.

Eric Lefkofsky is credited as a co-founder of successful companies like Tempus, InnerWorkings, Uptake, and LightBank. He drew inspiration from the success of InnerWorkings to teach at Chicago based business schools. These include the University of Chicago School of Business, Kellogg School of Management at Northwestern University and DePaul University’s Kellstadt Graduate School of Business.

Read More Click Here

Oncotarget is a weekly global medical journal that is peer-reviewed and focuses on the pathological basis of cancers and the treatment protocols employed in improving and managing the cancer patients. Oncotarget also put its focus on the management program impacts by exploring evidence on the new and existing therapies with the aim of improving the lives of the cancer patients. Being published in English, it allows the majority people around the globe to read it due to broad acceptance of the English language around the world.Through the publication of the journal by Mikhail Blasgosklonny, Oncotarget has gained an excellent reputation with an incredible impact.

Increased Publication

Due to the improvement in volume, quality, and impact, Oncotarget is now publishing two issues every week – on Tuesday and Friday. It has enabled the journal to relay highly crucial scientific information making it a leading journal. Oncotarget has also increased in popularity due to punctual, insightful, constructive, and multiple peer-review.It aims at making the scientific results widely and rapidly available to the readers with the help, guidance, and input of the most prominent scientist. The journal has helped researchers to contribute the progress of the science and its ultimate goal is to ensure life is without the diseases.

Why Oncotarget is the Best Journal

The journal has primarily provided the scientific research by eliminating the boundaries between different medical fields. The success of Oncotarget is also evident where it encourages and allows the editors to add more sections including Molecular Biology, Aging, Cardiology, Metabolism, Endocrinology, among many others.The Oncotarget website is freely accessible and people are free to use the information in conducting their research. An individual can extract particular details with the use of a unique search feature. It is quick, reliable, and informative.It has also perfected the art of using social media. Oncotarget has various social media accounts such as Facebook, and it remains the best journal to learn about scientific information.

In Fortune’s article “This Is What’s Missing in the Data Centric Approach to Cancer”, Barb Darrow discusses Erik Lefkofsky’s new venture.

Erik Lefkofsky is the co-founder and CEO Tempus. The startup was created to develop cancer databases to change cancer treatment into a combination of clinical data and molecular data.

He attended Fortune’s Brainstorm Health conference in San Diego where he discussed what’s missing from the current medical research system. Part of the problem today is that the researchers don’t have easy access to the data. For example, Lefkofsky states that “if you were to go into any of the cancer centers and ask who took Herceptin over two years and how they did, they’d need a grant and at least 90 days.”

Lefkosky started Tempus as a way to ameliorate the situation. Not only does it add technology to the existing electronic medical record, but it gathers the information and provides a unique approach to treatment. By creating a large aggregate data pool, the data for each individual can be used to discover patterns similarities between the results and the treatment.

The realization that drastic systematic change to cancer treatment was vital occurred after his wife was diagnosed with cancer. The constant trips to various doctors and specialists proved to be a disappointment when he realized that they simply didn’t have the data to interpret how the different treatments work for patients with similar molecular biology.

In addition to starting Tempus, Mr. Lefkofsky is also a co-founder of Groupon one of the largest global e-commerce marketplaces. He was a founding partner of Lightbank, a venture fund which invests in technology, and Uptake which is a leading analytics platform for some of the world’s most considerable industries.

Mr. Lefkosky and his wife are philanthropists who are dedicated to improving education, health care, human rights and the development of the arts. He founded Lefkosky Family Foundation with his wife in 2006 to improve high-impact programs that can drastically improve quality of life.

Learn More: lefkofskyfoundation.com/about-eric-lefkofsky/

Research

Getting good results after looking to find a solution to a health challenge like cancer takes the effort of experts in various specialties. Clay Siegall is among experts who have invested a lot to developing better cancer research methods. His idea is to come up with solutions that will put to an end the worry about cancer by developing reliable and strong cancer treatment methods. Although this is a field that has been around for many years, cancer research is yet to develop a fully reliable solution for the treatment of the disease.

Many companies and institutes have also chipped in to also do their part in the fight against cancer. Seattle Genetics, founded by Clay Siegall, has been key in delivering solutions that are developed with a focus on eliminating cancer. In a recent release, the company unveiled a new technology, the ADC Technology, which is quite promising and developed to offer an easier way of dealing with cancer. Through this technology, the cancer treatment process is made easier by the fact that it targets cancerous cells and kills them while sparing all healthy cells. This is unlike the popular methods that have been in use over the years since none could guarantee such a process. Several companies joined Seattle Genetics to support this revolutionary technology.

About Clay Siegall

Clay Siegall is a renowned scientist, who is the CEO and founder of a highly developed biotechnology company, Seattle Genetics. He supports research to develop highly effective and reliable cancer treatment methods and his company has helped in this space by producing the ADC Technology that makes treating cancer easier. He has also been working with the executives of other companies to chart ways forward and enter into strategic licenses that would allow joint effort in the fight to get a reliable cancer treatment method.

Between 1988 and 1991, Clay Siegall worked with the National Institute of Health and the National Cancer Institute. In 1991, he joined the Bristol-Meyers Squibb Pharmaceutical Institute, where he worked until 1997. In 1998, he founded Seattle Genetics and has been working as the CEO of the company.